Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
复制标题
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Yusen Zhou
中科院分区：
文献类型：
--
作者：
Yusen Zhou
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to further improve their efficacy.
